STAT Plus: Sarepta under new pressure as a competitor files with FDA for Duchenne drug
Sarepta Therapeutics is in more trouble.
The Japanese drugmaker NS Pharma said Wednesday that the paperwork required to seek approval for a new drug to treat Duchenne muscular dystrophy was submitted to the U.S. Food and Drug Administration.
